Assessment of Risk of Depression, Anxiety, and Stress among Type-2 Diabetic Patients on Oral Antidiabetics.

Active, not recruiting

Brief Summary: Type 2 diabetes mellitus (T2DM) and depression are prevalent conditions associated with limitations in daily functioning, reduced quality of life, and increased mortality rates. The occurrence and diagnosis of depression in individuals with T2DM have risen significantly, with research indicating that T2DM can lead to twice the likelihood of developing depression. Three biological pathways have been emphasized to cause depression in T2DM patients. First, it has been discovered that depressed symptoms are linked to hyperglycemia as determined by HbA1C. Secondly, various cell investigations, studies on animals, and clinical studies on humans have pointed to insulin resistance as the factor connecting depression and diabetes. Thirdly, increased inflammation has been observed in both diabetic and depressed patients. The hypothesis suggests that antidiabetic medications could potentially reduce the occurrence of depression in diabetic patients, as many of these drugs have impacts on all three pathways. Previous studies have shown that using any oral anti-diabetic medicine reduces the likelihood of developing depression. Our study specifically aims to assess the proportion of depression, anxiety, and stress among T2DM patients who are on metformin+sulphonylureas v/s SGLT2I+other OHAs v/s DPP4I+other OHAs.

Recruitment & Eligibility

Inclusion Criteria

Subjects on metformin+sulphonylureas/SGLT2I+other OHAs/DPP4I+other OHAs for at least 30 days prior to enrolment in the study 2.
Participants who are willing to give consent.

Exclusion Criteria

T2DM patients with life-threatening complications 2.
Pregnant women 3.
Patients taking SGLT2I, DPP4I in combination.
Patients who are severely disabled, deaf, or mute 5.
Patients taking antidepressants 6.
Patients with: (i)Neurological or severe psychiatric disease (ii)Depression or anxiety with onset prior to starting OHAs.

Primary Outcome Measures

Name	Time	Method
Depression	At baseline visit

Secondary Outcome Measures

Name	Time	Method
FBS	PPBS

Locations (1): Justice K. S. Hegde Charitable Hospital
🇮🇳
Kannada, KARNATAKA, India
Justice K. S. Hegde Charitable Hospital
🇮🇳Kannada, KARNATAKA, India
Dr Roopa Satyanarayan Basutkar
Principal investigator
9047155003
roopa.satyanarayan@nitte.edu.in